Harnessing the shift to continuous manufacturing for biologic therapies

European Pharmaceutical Review’s latest Pharma Horizons report provides insight on key developments in pharmaceutical biologics for drug development, pharmaceutical manufacturing and quality control.

This report delves into the latest developments impacting the pharmaceutical biologic drug sector today. Inside, articles explore current key topics including biosimilars, antibody drugs, manufacturing, drug delivery and vaccines.

Stay up to date with the latest developments in biologics including articles on:

Navigating the demanding biosimilar landscape and improving patient access to biologic therapies
Preventing infectious diseases with innovative vaccine development
Current trends and future outlook for achieving optimal quality control in antibody drug conjugate (ADC) drug development
The major challenges and solutions in continuous manufacturing of biologic therapeutics, highlighting quality control considerations
The potential of subcutaneous injectable drugs as a solution to overcome a key obstacle in biologic drug delivery.
Register now to access this exclusive content as we discover some of the challenges and opportunities for biologic drugs in pharma, with exclusive insight from:

Peter Stenico, Biosimilar Global Head and Country President Austria at Sandoz
Dr Hanneke Schuitemaker, Chief Scientific Officer of Valneva
Rashida Najmi, Chief Quality Officer, Piramal Pharma Limited
Dr Sundar Ramanan, Chief Quality Officer, Enzene Biosciences
Deborah Bitterfield, CEO of Lindy Biosciences.

Source : https://www.europeanpharmaceuticalreview.com/